Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 314

1.

Blocking IL-1β pathway following paclitaxel chemotherapy slightly inhibits primary tumor growth but promotes spontaneous metastasis.

Voloshin T, Alishekevitz D, Kaneti L, Miller V, Isakov E, Kaplanov I, Voronov E, Fremder E, Benhar M, Machluf M, Apte RN, Shaked Y.

Mol Cancer Ther. 2015 Apr 17. pii: molcanther.0969.2014. [Epub ahead of print]

PMID:
25887886
2.

Hypnotherapy for irritable bowel syndrome: an audit of one thousand adult patients.

Miller V, Carruthers HR, Morris J, Hasan SS, Archbold S, Whorwell PJ.

Aliment Pharmacol Ther. 2015 May;41(9):844-55. doi: 10.1111/apt.13145. Epub 2015 Mar 4.

PMID:
25736234
3.

Improving evidence developed from population-level experience with targeted agents.

McClellan MB, Daniel GW, Dickson D, Perlmutter J, Berger DP, Miller V, Nussbaum S, Malin J, Romine MH, Schilsky RL.

Clin Pharmacol Ther. 2015 May;97(5):478-87. doi: 10.1002/cpt.90. Epub 2015 Apr 3.

PMID:
25676878
4.

How can we exploit the brain's ability to repair itself?

Miller V, Gomez-Nicola D.

Expert Rev Neurother. 2014 Dec;14(12):1345-8. doi: 10.1586/14737175.2014.985659.

PMID:
25427149
5.

Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of advanced non-small-cell lung cancer (ATLAS).

Kabbinavar F, Fehrenbacher L, Hainsworth J, Kasubhai S, Kressel B, Marsland T, Patel T, Rubin M, White L, Yang JC, Klughammer B, Colburn D, Miller V, Johnson BE.

J Thorac Oncol. 2014 Sep;9(9):1411-7. doi: 10.1097/JTO.0000000000000274.

PMID:
25122437
6.

Irritable bowel syndrome: a comparison of subtypes.

Rey de Castro NG, Miller V, Carruthers HR, Whorwell PJ.

J Gastroenterol Hepatol. 2015 Feb;30(2):279-85. doi: 10.1111/jgh.12704.

PMID:
25091059
7.

Regulatory considerations for antiretroviral prophylaxis to prevent HIV acquisition.

Miller V, Grant RM.

Clin Pharmacol Ther. 2014 Aug;96(2):153-5. doi: 10.1038/clpt.2014.114. Review.

PMID:
25056397
8.

HIV and hepatitis C virus infection in the United States: whom and how to test.

Panneer N, Lontok E, Branson BM, Teo CG, Dan C, Parker M, Stekler JD, DeMaria A Jr, Miller V.

Clin Infect Dis. 2014 Sep 15;59(6):875-82. doi: 10.1093/cid/ciu396. Epub 2014 May 27.

PMID:
24867787
9.

Accelerating drug development through collaboration: the Hepatitis C Drug Development Advisory Group.

Hutchison C, Kwong A, Ray S, Struble K, Swan T, Miller V.

Clin Pharmacol Ther. 2014 Aug;96(2):162-5. doi: 10.1038/clpt.2014.113. Epub 2014 May 22. Review.

PMID:
24853733
10.

A multitiered strategy of simulation training, kit consolidation, and electronic documentation is associated with a reduction in central line-associated bloodstream infections.

Allen GB, Miller V, Nicholas C, Hess S, Cordes MK, Fortune JB, Blondin J, Ashikaga T, Ricci M.

Am J Infect Control. 2014 Jun;42(6):643-8. doi: 10.1016/j.ajic.2014.02.014.

PMID:
24837115
11.

Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.

Pirazzoli V, Nebhan C, Song X, Wurtz A, Walther Z, Cai G, Zhao Z, Jia P, de Stanchina E, Shapiro EM, Gale M, Yin R, Horn L, Carbone DP, Stephens PJ, Miller V, Gettinger S, Pao W, Politi K.

Cell Rep. 2014 May 22;7(4):999-1008. doi: 10.1016/j.celrep.2014.04.014. Epub 2014 May 9.

12.

Anti-VEGF-A affects the angiogenic properties of tumor-derived microparticles.

Munster M, Fremder E, Miller V, Ben-Tsedek N, Davidi S, Scherer SJ, Shaked Y.

PLoS One. 2014 Apr 21;9(4):e95983. doi: 10.1371/journal.pone.0095983. eCollection 2014.

13.

Regoaling: a conceptual model of how parents of children with serious illness change medical care goals.

Hill DL, Miller V, Walter JK, Carroll KW, Morrison WE, Munson DA, Kang TI, Hinds PS, Feudtner C.

BMC Palliat Care. 2014 Mar 13;13(1):9. doi: 10.1186/1472-684X-13-9.

14.

Beneficial impact of antiretroviral therapy on non-AIDS mortality.

Miller V, Hodder S.

AIDS. 2014 Jan 14;28(2):273-4. doi: 10.1097/QAD.0000000000000079. No abstract available.

PMID:
24413312
15.

Tumor-derived microparticles induce bone marrow-derived cell mobilization and tumor homing: a process regulated by osteopontin.

Fremder E, Munster M, Aharon A, Miller V, Gingis-Velitski S, Voloshin T, Alishekevitz D, Bril R, Scherer SJ, Loven D, Brenner B, Shaked Y.

Int J Cancer. 2014 Jul 15;135(2):270-81. doi: 10.1002/ijc.28678. Epub 2014 Jan 13.

PMID:
24347266
16.

Differential therapeutic effects of anti-VEGF-A antibody in different tumor models: implications for choosing appropriate tumor models for drug testing.

Alishekevitz D, Bril R, Loven D, Miller V, Voloshin T, Gingis-Velistki S, Fremder E, Scherer SJ, Shaked Y.

Mol Cancer Ther. 2014 Jan;13(1):202-13. doi: 10.1158/1535-7163.MCT-13-0356. Epub 2013 Oct 22.

17.

ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer.

Johnson BE, Kabbinavar F, Fehrenbacher L, Hainsworth J, Kasubhai S, Kressel B, Lin CY, Marsland T, Patel T, Polikoff J, Rubin M, White L, Yang JC, Bowden C, Miller V.

J Clin Oncol. 2013 Nov 1;31(31):3926-34. doi: 10.1200/JCO.2012.47.3983. Epub 2013 Oct 7.

18.

Response to the letter of Kawada T on adiponectin and the metabolic syndrome.

Calton EK, Miller V, Soares MJ.

Eur J Clin Nutr. 2013 Aug;67(8):897. doi: 10.1038/ejcn.2013.105. Epub 2013 Jun 19. No abstract available.

PMID:
23778787
19.

Multisystem dysregulation in painful temporomandibular disorders.

Chen H, Nackley A, Miller V, Diatchenko L, Maixner W.

J Pain. 2013 Sep;14(9):983-96. doi: 10.1016/j.jpain.2013.03.011. Epub 2013 May 28.

20.

Getting to normal: are we there yet?

Miller V, Horberg M.

AIDS. 2013 Mar 27;27(6):1027-8. doi: 10.1097/QAD.0b013e32835e39c6. No abstract available.

PMID:
23698066
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk